Table 2.
Various types of maturity-onset diabetes of the young and neonatal diabetes mellitus with the genes involved in the pathogenesis and the clinical features
|
|
Subtype
|
Gene
|
Frequency
|
Gene-disease
|
Clinical feature
|
Inheritance
|
| MODY | MODY 1 | HNF4A | 14% | Classical MODY | Fetal macrosomia and/or neonatal hypoglycemia, respond to low-dose SU initially, progressive β-cell failure, require insulin later, risks of complications | AD |
| MODY 2 | GCK | 22% | Mild fasting hyperglycemia does not require treatment except during gestation determined by the GCK mutation status of the foetus | AD, rarely AR | ||
| MODY 3 | HNF1A | 33% | Disproportionate glucosuria (low renal threshold), response to low-dose SU initially, progressive β-cell failure, require insulin later, risks of complications | AD, rarely AR | ||
| MODY 4 | IPF1/PDX1 | < 1% | A heterozygous mutation causing MODY or T2DM or homozygous mutation causing PNDM (see below) | AD | ||
| MODY 5 | HNF1B | 6% | Syndromic MODY | Renal cysts and diabetes, pancreas hypoplasia, exocrine insufficiency, β-cell defect, low magnesium, gout, altered LFT, and autism; Require insulin; Risks of complications; 40% are de novo | AD | |
| MODY 6 | NEUROD1 | 1% | Classical MODY | A heterozygous mutation causing MODY or homozygous mutation causing NDM (not mentioned below) | AD | |
| MODY 7 | KLF11 | < 1% | Evidence refuted | Potentially causing T2DM in the presence of obesity rather than causing MODY | AD | |
| MODY 8 | CEL | < 1% | Syndromic MODY | Diabetes and pancreatic exocrine dysfunction; Pancreatic cysts may be present | AD | |
| MODY 9 | PAX4 | < 1% | Evidence refuted | Potentially causing T2DM in the presence of obesity rather than causing MODY | AD | |
| MODY 10 | INS | 2% | Classical MODY | Mild defects can present as MODY whereas severe defects can present as TNDM or PNDM (as below), insulin treatment preserves β-cell mass and insulin secretion | AD | |
| MODY 11 | BLK | < 1% | Evidence refuted | Potentially causing T2DM in the presence of obesity rather than causing MODY | AD | |
| MODY 12 | ABCC8 | 4% | Classical MODY | Manifest as relapse following TNDM or as isolated MODY with no history of TNDM, respond to low-dose SU | AD | |
| MODY 13 | KCNJ11 | 2% | Manifest as relapse following TNDM or as isolated MODY with no history of TNDM, respond to low-dose SU | AD | ||
| MODY 14 | APPL1 | < 1% | Evidence weak | Delayed onset MODY with low penetrance and less severity; Potentially causing T2DM in the presence of obesity rather than causing MODY | AD | |
| RFX6-MODY | RFX6 | < 1% | Classical MODY | Significantly low penetrance; Likely to respond to DPP4 inhibitors or GLP-1 receptor agonists (low GIP levels are present in these patients) | AD | |
| NDM | TNDM 45% NDM | ZAC and HYMAI | 70% TNDM | TNDM1 | 6q24 abnormal uniparental disomy 40%, paternal duplication 40%, maternal hypomethylation 20%, macroglossia, umbilical hernia, cardiac/renal defect, hypothyroidism | Sporadic or AD |
| ABCC8 | 15% TNDM | TNDM2 | TNDM (early infancy), remission (early childhood), and/or relapse of diabetes (in adulthood), mild developmental features may be seen, marked response to low-dose SU | Sporadic or AD | ||
| KCNJ11 | 10% TNDM | TNDM (early infancy), remission (early childhood), and/or relapse of diabetes (in adulthood), mild developmental features may be seen, marked response to low-dose SU | Sporadic or AD | |||
| INS | 5% TNDM | IUGR; Doesn’t respond to SU but responds to insulin therapy | AD, rarely AR | |||
| HNF1B | Renal cyst and pancreatic hypoplasia | AD | ||||
| SLC2A2 | TNDM, PNDM (rare), or Fanconi-Bickel syndrome (Fanconi syndrome, short stature, rickets, growth retardation, hepatomegaly, and glucose/galactose intolerance) | AR | ||||
| PNDM 45% NDM | KCNJ11 | 50% PNDM | DEND (developmental delay, epilepsy, NDM) or iDEND syndrome (mild developmental delay, no epilepsy), severe hyperglycemia, DKA frequent, response to high-dose SU | Sporadic or AD | ||
| INS | 30% PNDM | IUGR; Doesn’t respond to SU but responds to insulin therapy | AD | |||
| ABCC8 | 15% PNDM | DEND (developmental delay, epilepsy, NDM) or iDEND syndrome (mild developmental delay, no epilepsy), severe hyperglycemia, DKA frequent, response to high-dose SU | Sporadic, AD or AR | |||
| GCK | 3% PNDM | IUGR; Homozygous mutations causing PNDM requiring lifelong insulin therapy | AR | |||
| IPF1/PDX1 | 2% PNDM | Pancreatic hypoplasia causing PNDM (homozygous mutation) | AR | |||
| HNF1B | Renal cyst and pancreatic hypoplasia | AD | ||||
| Syndromic NDM; 10% NDM | EIF2AK3 | Rare | PNDM with spondyloepiphyseal dysplasia, and renal anomalies (Wolcott-Rallison syndrome) | AR | ||
| FOXP3 | IPEX syndrome | XR | ||||
| GATA4/6 | Permanent neonatal diabetes with pancreatic agenesis and congenital heart defects | AD | ||||
| RFX6 | Neonatal diabetes, pancreatic hypoplasia, gallbladder agenesis, intestinal atresia (Mitchell-Riley syndrome) | AR | ||||
| GLIS3 | Congenital hypothyroidism, glaucoma, hepatic fibrosis, polycystic kidneys, developmental delay | AR | ||||
| PTF1A | Pancreatic and cerebellar hypoplasia | AR |
MODY: Maturity-onset diabetes of the young; NDM: Neonatal diabetes mellitus; TNDM: Transient neonatal diabetes mellitus; PNDM: Permanent neonatal diabetes mellitus; AD: Autosomal dominant; AR: Autosomal recessive; XR: X-linked recessive; SU: Sulfonylurea; LFT: Liver function test; T2DM: Type 2 diabetes mellitus; DPP4: Dipeptidyl peptidase-4; GLP: Glucagon-like peptide; IUGR: Intrauterine growth restriction; DEND: Developmental delay, epilepsy, neonatal diabetes mellitus; iDEND: Intermediate developmental delay, epilepsy, and neonatal diabetes syndrome; DKA: Diabetic ketoacidosis; IPEX syndrome: Immuno-dysregulation, polyendocrinopathy, enteropathy, X-linked.